JUPITER, Florida | January 29, 2026 — Myosin Therapeutics, a clinical-stage biotechnology company focused on first-in-class oncology therapies, has been invited to present at Biocom California’s Global Partnering & Investor Conference, scheduled for February 24–26, 2026, in La Jolla, California. The invitation underscores growing industry and investor interest in MT-125, the company’s lead investigational therapy for glioblastoma (GBM), as Myosin approaches key clinical milestones and strategic inflection points in 2026.
Science Significance
At the core of Myosin Therapeutics’ pipeline is MT-125, a first-in-class dual NMIIA/IIB inhibitor that targets cancer cell mechanics rather than traditional oncogenic signaling pathways. This differentiated approach is grounded in the scientific insight that aggressive tumors rely heavily on conserved cellular motor proteins to support invasion, survival, and resistance to therapy. By inhibiting molecular nanomotors, MT-125 aims to disrupt fundamental biomechanical processes essential for tumor progression. Supported by peer-reviewed publications in leading journals such as Cell, Myosin’s platform represents a novel scientific strategy with the potential to open new therapeutic avenues across multiple treatment-refractory cancers, including GBM and acute myeloid leukemia (AML).
Regulatory Significance
From a regulatory perspective, Myosin Therapeutics has achieved several important milestones that enhance the development trajectory of MT-125. The program is advancing under FDA IND 170975 and has received both FDA Orphan Drug Designation for malignant gliomas and FDA Fast Track Designation for glioblastoma. These designations reflect the high unmet medical need in GBM and provide regulatory incentives, including the potential for accelerated review, enhanced FDA engagement, and market exclusivity if approved. The upcoming STAR-GBM Phase 1/2 safety readout, expected in 2026, is positioned as a critical data catalyst to support immediate progression into Phase 2 dose expansion.
Business Significance
Advertisement
The Biocom California Global Partnering & Investor Conference is widely regarded as a premier venue for biotech deal-making, strategic alliances, and capital formation. Myosin’s selection to present places the company among a curated group of emerging innovators engaging directly with investors, pharmaceutical partners, and business development leaders. With a layered global intellectual property estate extending protection into 2040, Myosin is strategically positioned for licensing, co-development, or M&A discussions. The company’s orphan-first strategy emphasizes capital efficiency, focused execution, and scalable growth, aligning well with current investor priorities in the biotech sector.
Patients’ Significance
For patients, particularly those living with glioblastoma, the implications of Myosin’s progress are substantial. GBM remains one of the most aggressive and lethal brain cancers, with limited effective treatment options and poor long-term survival outcomes. MT-125 offers a novel mechanism of action that may complement or overcome resistance to existing therapies. The company’s focus on clinically meaningful endpoints, site readiness, and practical trial execution reflects a patient-centered approach aimed at accelerating access to innovative treatments. Planned expansion into AML and other refractory cancers further broadens the potential patient impact.
Policy Significance
Myosin Therapeutics’ development strategy aligns closely with broader health policy priorities aimed at encouraging innovation in rare and high-mortality diseases. Regulatory frameworks supporting orphan drug development, fast-track pathways, and non-dilutive federal funding play a critical role in enabling smaller biotech companies to advance transformative therapies. By leveraging these mechanisms, Myosin contributes to a policy ecosystem that promotes scientific risk-taking, faster clinical translation, and improved outcomes for underserved patient populations.
As Myosin Therapeutics prepares to engage global stakeholders at Biocom California’s Global Partnering & Investor Conference, the company enters 2026 with growing momentum. Anchored by MT-125’s advancing clinical program, strong regulatory positioning, and a differentiated scientific platform targeting cancer cell mechanics, Myosin is poised for its next phase of growth. The upcoming STAR-GBM data readout and planned Phase 2 expansion are expected to be defining milestones, reinforcing the company’s ambition to build a durable oncology franchise and deliver meaningful innovation for patients facing some of the most challenging cancers.
Source: Myosin Therapeutics press release
